/filters:format(webp)https://news.stocktwits-cdn.com/large_viking_jpg_7a4076836e.webp)
Latest Earnings Results: Q1 '26
Estimated EPS
-$0.98
Reported EPS
-$1.37
Surprise
-40.43%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
Reported GAAP EPS of -$1.10 down -89.66% YoY
Bullish Takeaway
Viking Therapeutics is advancing its obesity franchise with fully enrolled Phase 3 subcutaneous trials, planned oral Phase 3 initiation, and the successful expansion of its pipeline with new clinical programs.
Bearish Takeaway
Viking Therapeutics experienced an increased net loss driven by higher research and development expenses, while the company also saw a decrease in its total cash and short-term investment position.
Generated by Stocktwits using AI and company-reported earnings data for Q1 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q2 '26 | -$1.23 | -- | -- | N/A |
Q1 '26 | -$0.98 | -$1.37 | -40.43% | MISSED |
Q4 '25 | -$0.90 | -$1.38 | -53.80% | MISSED |
Q3 '25 | -$0.70 | -$0.81 | -15.17% | MISSED |
Q2 '25 | -$0.45 | -$0.58 | -29.90% | MISSED |
